Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2010 (2010), Article ID 480260, 9 pages
http://dx.doi.org/10.4061/2010/480260
Review Article

Treatment of Advanced Parkinson's Disease

1New York University School of Medicine, Department of Neurology, Division of Movement Disorders, New York, NY 10016, USA
2Robert Wood Johnson Medical School, Johnson Rehabilitation Institute, Edison, NJ 08818, USA

Received 13 August 2010; Accepted 20 December 2010

Academic Editor: Ray Chaudhuri

Copyright © 2010 Sara Varanese et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. M. Hoehn and M. D. Yahr, “Parkinsonism: onset, progression and mortality,” Neurology, vol. 17, no. 5, pp. 427–442, 1967. View at Google Scholar · View at Scopus
  2. M. M. Hoehn, “Parkinsonism treated with levodopa: progression and mortality,” Journal of Neural Transmission, vol. 19, supplement, pp. 253–264, 1983. View at Google Scholar · View at Scopus
  3. W. H. Poewe and G. K. Wenning, “The natural history of Parkinson' disease,” Annals of Neurology, vol. 44, no. 3, pp. S1–S9, 1998. View at Google Scholar · View at Scopus
  4. W. H. Poewe, A. J. Lees, and G. M. Stern, “Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study,” Neurology, vol. 36, no. 11, pp. 1528–1530, 1986. View at Google Scholar · View at Scopus
  5. A. Schrag and N. Quinn, “Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study,” Brain, vol. 123, no. 11, pp. 2297–2305, 2000. View at Google Scholar · View at Scopus
  6. T. N. Chase, M. M. Mouradian, and T. M. Engber, “Motor response complications and the function of striatal efferent systems,” Neurology, vol. 43, no. 12, pp. S23–S27, 1993. View at Google Scholar · View at Scopus
  7. K. R. Chaudhuri, D. G. Healy, and A. H. V. Schapira, “Non-motor symptoms of Parkinson's disease: diagnosis and management,” Lancet Neurology, vol. 5, no. 3, pp. 235–245, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. C. H. Williams-Gray, T. Foltynie, S. J. G. Lewis, and R. A. Barker, “Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options,” CNS Drugs, vol. 20, no. 6, pp. 477–505, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Aarsland, L. Marsh, and A. Schrag, “Neuropsychiatric symptoms in Parkinson's disease,” Movement Disorders, vol. 24, no. 15, pp. 2175–2186, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. A. Schrag, M. Jahanshahi, and N. Quinn, “What contributes to quality of life in patients with Parkinson's disease?” Journal of Neurology Neurosurgery and Psychiatry, vol. 69, no. 3, pp. 308–312, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Nussbaum, T. A. Treves, R. Inzelberg, J. M. Rabey, and A. D. Korczyn, “Survival in Parkinson's disease: the effect of dementia,” Parkinsonism and Related Disorders, vol. 4, no. 4, pp. 179–181, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. C. G. Goetz and G. T. Stebbins, “Risk factors for nursing home placement in advanced Parkinson's disease,” Neurology, vol. 43, no. 11, pp. 2227–2229, 1993. View at Google Scholar · View at Scopus
  13. D. Aarsland, J. P. Larsen, K. Karlsen, N. G. Lim, and E. Tandberg, “Mental symptoms in Parkinson's disease are important contributors to caregiver distress,” International Journal of Geriatric Psychiatry, vol. 14, no. 10, pp. 866–874, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. R. M. Pickering, Y. A. M. Grimbergen, U. Rigney et al., “A meta-analysis of six prospective studies of falling in Parkinson's disease,” Movement Disorders, vol. 22, no. 13, pp. 1892–1900, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. G. K. Kerr, C. J. Worringham, M. H. Cole, P. F. Lacherez, J. M. Wood, and P. A. Silburn, “Predictors of future falls in Parkinson disease,” Neurology, vol. 75, no. 2, pp. 116–124, 2010. View at Publisher · View at Google Scholar · View at PubMed
  16. V. A. Goodwin, S. H. Richards, R. S. Taylor, A. H. Taylor, and J. L. Campbell, “The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis,” Movement Disorders, vol. 23, no. 5, pp. 631–640, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. E. Moro, C. Hamani, Y. Y. Poon et al., “Unilateral pedunculopontine stimulation improves falls in Parkinson's disease,” Brain, vol. 133, no. 1, pp. 215–224, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. A. E. Lang and A. M. Lozano, “Medical progress: Parkinson’s disease—I,” The New England Journal of Medicine, vol. 339, pp. 1044–1055, 1998. View at Google Scholar
  19. A. E. Lang and A. M. Lozano, “Medical progress: Parkinson’s disease—II,” The New England Journal of Medicine, vol. 339, pp. 1130–1143, 1998. View at Google Scholar
  20. D. E. Riley and A. E. Lang, “The spectrum of levodopa-related fluctuations in Parkinson's disease,” Neurology, vol. 43, no. 8, pp. 1459–1464, 1993. View at Google Scholar · View at Scopus
  21. C. H. Waters, “Managing the late complications of Parkinson's disease,” Neurology, vol. 49, no. 1, pp. S49–S57, 1997. View at Google Scholar · View at Scopus
  22. W. C. Koller and R. Pahwa, “Treating motor fluctuations with controlled-release levodopa preparations,” Neurology, vol. 44, no. 7, pp. S23–28, 1994. View at Google Scholar · View at Scopus
  23. L. V. Metman, J. Hoff, M. M. Mouradian, and T. N. Chase, “Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa,” Movement Disorders, vol. 9, no. 4, pp. 463–465, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. M. C. Kurth, J. W. Tetrud, I. Irwin, W. H. Lyness, and J. W. Langston, “Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study,” Neurology, vol. 43, no. 5, pp. 1036–1039, 1993. View at Google Scholar · View at Scopus
  25. M. Pierantozzi, A. Pietroiusti, L. Brusa et al., “Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations,” Neurology, vol. 66, no. 12, pp. 1824–1829, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. F. Stocchi, L. Fabbri, L. Vecsei, A. Krygowska-Wajs, P. A. Monici Preti, and S. A. Ruggieri, “Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease,” Clinical Neuropharmacology, vol. 30, no. 1, pp. 18–24, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. R. Hardoff, M. Sula, A. Tamir et al., “Gastric emptying time and gastric motility in patients with Parkinson's disease,” Movement Disorders, vol. 16, no. 6, pp. 1041–1047, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. R. Kurlan, J. G. Nutt, W. R. Woodward et al., “Duodenal and gastric delivery of levodopa in parkinsonism,” Annals of Neurology, vol. 23, no. 6, pp. 589–595, 1988. View at Google Scholar · View at Scopus
  29. J. Samanta and R. A. Hauser, “Duodenal levodopa infusion for the treatment of Parkinson's disease,” Expert Opinion on Pharmacotherapy, vol. 8, no. 5, pp. 657–664, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. A. Antonini, I. U. Isaias, M. Canesi et al., “Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome,” Movement Disorders, vol. 22, no. 8, pp. 1145–1149, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. D. Devos, Y. Agid, A. Al Khedr et al., “Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease,” Movement Disorders, vol. 24, no. 7, pp. 993–1000, 2009. View at Publisher · View at Google Scholar · View at PubMed
  32. H. Honig, A. Antonini, P. Martinez-Martin et al., “Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life,” Movement Disorders, vol. 24, no. 10, pp. 1468–1474, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. H. L. Tyne, J. Parsons, A. Sinnott, S. H. Fox, N. A. Fletcher, and M. J. Steiger, “A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease,” Journal of Neurology, vol. 251, no. 11, pp. 1370–1374, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. M. R. Luquin, O. Scipioni, J. Vaamonde, O. Gershanik, and J. A. Obeso, “Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification,” Movement Disorders, vol. 7, no. 2, pp. 117–124, 1992. View at Google Scholar · View at Scopus
  35. J. P. Bennett, E. R. Landow, and L. A. Schuh, “Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms,” Neurology, vol. 46, pp. 1059–1062, 1996. View at Google Scholar
  36. G. J. Gomez Arevalo and O. S. Gershanik, “Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study,” Movement Disorders, vol. 43, pp. 1551–1555, 1993. View at Google Scholar · View at Scopus
  37. H. A. Hanagasi, G. Kaptanoglu, H. A. Sahin, and M. Emre, “The use of NMDA antagonist memantine in drug-resitant dyskinesia resulting from L-dopa,” Movement Disorders, vol. 15, pp. 1016–1017, 2000. View at Google Scholar
  38. S. Varanese, J. Howard, and A. Di Rocco, “NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease,” Movement Disorders, vol. 25, no. 4, pp. 508–510, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. E. Cereda, M. Barichella, and G. Pezzoli, “Controlled-protein dietary regimens for Parkinson's disease,” Nutritional Neuroscience, vol. 13, no. 1, pp. 29–32, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. H. Braak, K. Del Tredici, U. Rüb, R. A. I. De Vos, E. N. H. Jansen Steur, and E. Braak, “Staging of brain pathology related to sporadic Parkinson's disease,” Neurobiology of Aging, vol. 24, no. 2, pp. 197–211, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Aarsland, J. P. Larsen, E. Tandberg, and K. Laake, “Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study,” Journal of the American Geriatrics Society, vol. 48, no. 8, pp. 938–942, 2000. View at Google Scholar · View at Scopus
  42. K. R. Chaudhuri, A. H. V. Schapira, P. Martinez-Martin et al., “The holistic management of Parkinson’s using a novel non-motor symptom scale and questionnaire,” Advances in Clinical Neuroscience and Rehabilitation, vol. 4, pp. 20–24, 2004. View at Google Scholar
  43. K. R. Chaudhuri, P. Martinez-Martin, R. G. Brown et al., “The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study,” Movement Disorders, vol. 22, no. 13, pp. 1901–1911, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. P. Martinez-Martin, C. Rodriguez-Blazquez, K. Abe et al., “International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease,” Neurology, vol. 73, no. 19, pp. 1584–1591, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. C. H. Williams-Gray, T. Foltynie, S. J. G. Lewis, and R. A. Barker, “Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options,” CNS Drugs, vol. 20, no. 6, pp. 477–505, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Emre, “Dementia associated with Parkinson's disease,” Lancet Neurology, vol. 2, no. 4, pp. 229–237, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Aarsland, I. Litvan, D. Salmon, D. Galasko, T. Wentzel-Larsen, and J. P. Larsen, “Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 74, no. 9, pp. 1215–1220, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. C. G. Ballard, D. Aarsland, I. McKeith et al., “Fluctuations in attention: PD dementia vs DLB with parkinsonism,” Neurology, vol. 59, no. 11, pp. 1714–1720, 2002. View at Google Scholar · View at Scopus
  49. S. Varanese, B. Perfetti, D. Monaco et al., “Fluctuating cognition and different cognitive and behavioural profiles in Parkinson's disease with dementia: comparison of dementia with Lewy bodies and Alzheimer's disease,” Journal of Neurology, vol. 257, no. 6, pp. 1004–1011, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. J. O. Rinne, R. Portin, H. Ruottinen et al., “Cognitive impairment and the brain dopaminergic system in Parkinson disease,” Archives of Neurology, vol. 57, no. 4, pp. 470–475, 2000. View at Google Scholar · View at Scopus
  51. B. Dubois, M. Ruberg, and F. Javoy Agid, “A subcortico-cortical cholinergic system is affected in Parkinson's disease,” Brain Research, vol. 288, no. 1-2, pp. 213–218, 1983. View at Google Scholar · View at Scopus
  52. M. Emre, D. Aarsland, A. Albanese et al., “Rivastigmine for dementia associated with Parkinson's disease,” New England Journal of Medicine, vol. 351, no. 24, pp. 2509–2518, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. D. Aarsland, K. Laake, J. P. Larsen, and C. Janvin, “Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study,” Journal of Neurology Neurosurgery and Psychiatry, vol. 72, no. 6, pp. 708–712, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. I. Leroi, J. Brandt, S. G. Reich et al., “Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease,” International Journal of Geriatric Psychiatry, vol. 19, no. 1, pp. 1–8, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. S. A. Factor, E. S. Molho, G. D. Podskalny, and D. Brown, “Parkinson's disease: drug-induced psychiatric states,” Advances in Neurology, vol. 65, pp. 115–138, 1995. View at Google Scholar · View at Scopus
  56. B. Ravina, K. Marder, H. H. Fernandez et al., “Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH Work Group,” Movement Disorders, vol. 22, no. 8, pp. 1061–1068, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. The Parkinson Study Group, “Low dose clozapine for the treatment of drug-induced psychosis in parkinson’s disease,” The New England Journal of Medicine, vol. 340, pp. 757–763, 1999. View at Google Scholar
  58. A. Schrag, P. Barone, R. G. Brown et al., “Depression rating scales in Parkinson's disease: critique and recommendations,” Movement Disorders, vol. 22, no. 8, pp. 1077–1092, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. B. L. Kagan, D. L. Sultzer, N. Rosenlicht, and R. H. Gerner, “Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial,” American Journal of Psychiatry, vol. 147, no. 5, pp. 591–595, 1990. View at Google Scholar · View at Scopus
  60. A. D. Rocco, J. D. Rogers, R. Brown, P. Werner, and T. Bottiglieri, “S-adenosyl-methionine improves depression in patients with Parkinson's disease in an open-label clinical trial,” Movement Disorders, vol. 15, no. 6, pp. 1225–1229, 2000. View at Google Scholar · View at Scopus
  61. R. A. Hauser, M. N. Wahba, T. A. Zesiewicz, and W. Anderson, “Modafinil treatment of pramipexole-associated somnolence,” Movement Disorders, vol. 15, no. 6, pp. 1269–1271, 2000. View at Google Scholar · View at Scopus
  62. H. Lahrmann, P. Cortelli, M. Hilz, C. J. Mathias, W. Struhal, and M. Tassinari, “EFNS guidelines on the diagnosis and management of orthostatic hypotension,” European Journal of Neurology, vol. 13, no. 9, pp. 930–936, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. W. H. Jost, “Gastrointestinal dysfunction in Parkinson's Disease,” Journal of the Neurological Sciences, vol. 289, no. 1-2, pp. 69–73, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. H. Blackett, R. Walker, and B. Wood, “Urinary dysfunction in Parkinson's disease: a review,” Parkinsonism and Related Disorders, vol. 15, no. 2, pp. 81–87, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. K. E. Andersson, C. R. Chapple, L. Cardozo et al., “Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence,” Current Opinion in Urology, vol. 19, no. 4, pp. 380–394, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. J. Jankovic, “Disease-oriented approach to botulinum toxin use,” Toxicon, vol. 54, no. 5, pp. 614–623, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. S. M. Calne and A. Kumar, “Nursing care of patients with late-stage Parkinson's disease,” The Journal of Neuroscience Nursing, vol. 35, no. 5, pp. 242–251, 2003. View at Google Scholar · View at Scopus
  68. S. Sapir, J. L. Spielman, L. O. Ramig, B. H. Story, and C. Fox, “Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings,” Journal of Speech, Language, and Hearing Research, vol. 50, no. 4, pp. 899–912, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. D. B. Calne and S. Calne, “Treatment of Parkinson’s disease,” in Therapeutics in Geriatric Neuropsychiatry, R. J. Ancil, S. G. Holliday, and A. H. Mithani, Eds., pp. 1–12, John Wiley & Sons, Chichester, England, 1997. View at Google Scholar